BG99261A - Steroid glycosides for the treatment of hyperchlesterolemia - Google Patents

Steroid glycosides for the treatment of hyperchlesterolemia

Info

Publication number
BG99261A
BG99261A BG99261A BG9926194A BG99261A BG 99261 A BG99261 A BG 99261A BG 99261 A BG99261 A BG 99261A BG 9926194 A BG9926194 A BG 9926194A BG 99261 A BG99261 A BG 99261A
Authority
BG
Bulgaria
Prior art keywords
treatment
hyperchlesterolemia
steroid glycosides
steroid
glycosides
Prior art date
Application number
BG99261A
Other languages
Bulgarian (bg)
English (en)
Inventor
Michael Deninno
Peter Mccarthy
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG99261A publication Critical patent/BG99261A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BG99261A 1992-06-26 1994-12-13 Steroid glycosides for the treatment of hyperchlesterolemia BG99261A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90491492A 1992-06-26 1992-06-26
PCT/US1993/004092 WO1994000480A1 (fr) 1992-06-26 1993-05-06 Glycosides steroidiens utiles dans le traitement de l'hypercholesterolemie

Publications (1)

Publication Number Publication Date
BG99261A true BG99261A (en) 1995-06-30

Family

ID=25419965

Family Applications (1)

Application Number Title Priority Date Filing Date
BG99261A BG99261A (en) 1992-06-26 1994-12-13 Steroid glycosides for the treatment of hyperchlesterolemia

Country Status (19)

Country Link
US (2) US5629295A (fr)
EP (4) EP0796864A2 (fr)
JP (2) JPH07504921A (fr)
KR (1) KR950702203A (fr)
CN (1) CN1085561A (fr)
AP (1) AP489A (fr)
AU (1) AU4226593A (fr)
BG (1) BG99261A (fr)
BR (1) BR9306619A (fr)
CA (1) CA2139104A1 (fr)
CZ (1) CZ331094A3 (fr)
HR (1) HRP930994A2 (fr)
IL (1) IL106055A0 (fr)
MX (1) MX9303826A (fr)
OA (1) OA10121A (fr)
RU (1) RU94046294A (fr)
SK (1) SK158394A3 (fr)
WO (1) WO1994000480A1 (fr)
YU (1) YU44793A (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0647233A1 (fr) * 1992-06-26 1995-04-12 Pfizer Inc. PROCEDE DE SYNTHESE DE $g(b)-O-CELLOBIOSIDE HEPTAALCANOATE STEROIDIEN
CZ280195A3 (en) * 1993-04-28 1996-02-14 Pfizer Crystalline spirostanyl glycoside, monohydrate thereof, pharmaceutical composition based thereon and process for preparing crystalline steroidal glycoside
US5502038A (en) * 1993-06-21 1996-03-26 Medical Research Foundation Of Oregon Cholesterol sequestrant glycosides that inhibit intestinal cholesterol absorption
ES2074006B1 (es) * 1993-07-05 1996-03-16 Pfizer Glicosidos esteroidales para tratar hipercolesterolemia.
FI96243C (fi) * 1993-10-26 1996-05-27 Ilmari Paakkinen Menetelmä ja laite rakeisten maamassojen ominaisuuksien mittaamiseksi
EP0737202A1 (fr) * 1993-12-28 1996-10-16 Pfizer Inc. Agents hypocholesterolemiques
AU7948494A (en) * 1993-12-28 1995-07-17 Pfizer Inc. Steroidal glycosides
FR2722690B1 (fr) * 1994-07-21 1996-10-25 Univ Montpellier Ii Compositions de saponines et/ou de leurs formes aglycones et leurs applications comme medicaments
PL318937A1 (en) * 1994-08-30 1997-07-21 Pfizer Spirostanyloglycoside crystals
CA2200436A1 (fr) * 1994-09-20 1996-04-04 Pfizer Inc. Combinaison d'un inhibiteur d'absorption du cholesterole et d'un inhibiteur de synthese du cholesterol
US6150336A (en) * 1995-05-29 2000-11-21 Pfizer Inc. Steroidal glycosides
US5698527A (en) * 1995-08-08 1997-12-16 Merck & Co., Inc. Steroidal glycosides as antihyperlipidemic agents
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
DE69929177T2 (de) * 1998-03-26 2006-08-24 Phytopharm Plc, Godmanchester Smilagenin und anzurogenin-d zur behandlung der alzheimerischen krankheit
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
JP3370610B2 (ja) * 1998-08-21 2003-01-27 武田薬品工業株式会社 害虫防除剤
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
US6343258B1 (en) 1999-08-13 2002-01-29 ALEXIS Brian Method for testing for readiness for harvesting of tribulus terrestris l. having high steroidal saponin content
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AU1122301A (en) * 1999-11-01 2001-05-14 Forbes Medi-Tech Inc. Novel glycosides comprising pentose mono-, di-, tri-, or oligosaccharides and phytosterols and/or phytostanols
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
US6207638B1 (en) 2000-02-23 2001-03-27 Pacifichealth Laboratories, Inc. Nutritional intervention composition for enhancing and extending satiety
US6429190B1 (en) 2000-12-15 2002-08-06 Pacifichealth Laboratories, Inc. Method for extending the satiety of food by adding a nutritional composition designed to stimulate cholecystokinin(CCK)
WO2002047614A2 (fr) 2000-12-15 2002-06-20 Pacific Health Laboratories, Inc. Composition nutritionnelle destinee a ameliorer l'efficacite d'un inhibiteur de lipase
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
US6703530B2 (en) * 2002-02-28 2004-03-09 General Electric Company Chemical reactor system and process
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
CN102727501A (zh) * 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途
KR101092150B1 (ko) * 2002-10-28 2011-12-12 파이토팜 피엘씨 사포겐-3-온의 입체특이적 환원
CA2590533C (fr) 2004-11-23 2010-09-07 Warner-Lambert Company Llc Derives d'acide 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoique comme inhibiteurs de hmg co-a reductase pour le traitement de l'hyperlipidemie
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
CN102066397B (zh) * 2008-04-18 2013-09-11 里亚塔医药公司 包含抗炎症药效团的化合物以及使用方法
EP2309860B1 (fr) * 2008-07-22 2014-01-08 Trustees of Dartmouth College Cyanoénones monocycliques et leurs procédés d'utilisation
EP2571860A1 (fr) 2010-05-21 2013-03-27 Pfizer Inc 2-phénylbenzoylamides
EP2680874A2 (fr) 2011-03-04 2014-01-08 Pfizer Inc Peptides de type edn3 et utilisations associées
CU20110244A7 (es) * 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
MX2021008533A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3178418A (en) 1963-02-26 1965-04-13 Glaxo Lab Ltd Monobromination at the 11-position of hecogenin and 3-lower alkanoyl esters thereof
DE2926463A1 (de) * 1978-07-05 1980-01-24 Roecar Holdings Nv Spiroketaline und ihre verwendung
US4260603A (en) * 1979-01-02 1981-04-07 Pegel Karl H Sterol glycoside with activity as prostaglandin synthetase inhibitor
NZ193564A (en) * 1979-05-02 1985-01-31 Aruba Pty Ltd Steroid alkaloids from solanum sodomeum and pharmaceutical compositions
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
ES524614A0 (es) * 1982-08-12 1984-05-01 Nativelle Sa Ets Procedimiento de preparacion de nuevos amino-14 esteroides.
ES524796A0 (es) * 1982-08-20 1984-05-01 Nativelle Sa Ets Procedimiento de preparacion de nuevos derivos de amino-14 esteroides
IT1188184B (it) 1985-08-14 1988-01-07 Texcontor Ets Sali ammonici quaternari di polisaccaridi ad attivita' ipocolesterolemizzante
US5017562A (en) * 1987-02-11 1991-05-21 Regents Of The University Of Minnesota Crystalline saponin-containing complex
FR2621316B1 (fr) * 1987-10-02 1991-06-21 Nativelle Sa Ets Nouveaux esters d'acide androstane 17-carboxylique, procede pour leur preparation, et medicament les contenant
US5010185A (en) * 1989-06-13 1991-04-23 Pfizer Inc. Processes for tigogenin beta-cellobioside
EP0524595A1 (fr) * 1991-07-23 1993-01-27 Schering Corporation Dérivés de bêta-lactame substitués comme agents hypocholestérolémiques et leurs procédés de préparation
AU2675092A (en) * 1991-09-27 1993-04-27 Procter & Gamble Pharmaceuticals, Inc. Use of 14-aminosteroids for the manufacture of a medicament to slow the rate of progression of myocardial structural damages characteristic of congestive heart failure
DE69225233T2 (de) * 1991-10-04 1998-11-19 Procter & Gamble Cholesterinsenkende Verbindungen und Verfahren zu ihrer Herstellung
JPH0826064B2 (ja) * 1991-11-25 1996-03-13 ファイザー インク. ステロイドペルアシルグリコシド類の製法
US5530107A (en) * 1992-10-15 1996-06-25 Pfizer Inc. Method for making steroidal peracyl glycosides
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents

Also Published As

Publication number Publication date
KR950702203A (ko) 1995-06-19
HRP930994A2 (en) 1996-08-31
CN1085561A (zh) 1994-04-20
IL106055A0 (en) 1993-10-20
MX9303826A (es) 1994-02-28
EP0796863A2 (fr) 1997-09-24
CA2139104A1 (fr) 1994-01-06
US5629295A (en) 1997-05-13
BR9306619A (pt) 1998-12-08
JPH07504921A (ja) 1995-06-01
US5703052A (en) 1997-12-30
RU94046294A (ru) 1996-10-10
WO1994000480A1 (fr) 1994-01-06
SK158394A3 (en) 1995-05-10
EP0647234A1 (fr) 1995-04-12
EP0796862A2 (fr) 1997-09-24
CZ331094A3 (en) 1995-09-13
YU44793A (sh) 1996-10-09
AU4226593A (en) 1994-01-24
AP489A (en) 1996-05-02
AP9300539A0 (en) 1993-07-31
OA10121A (en) 1996-12-18
EP0796864A2 (fr) 1997-09-24
JPH09309897A (ja) 1997-12-02

Similar Documents

Publication Publication Date Title
BG99261A (en) Steroid glycosides for the treatment of hyperchlesterolemia
BG104247A (en) Resorcinol derivatives
EE9900481A (et) Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks
UA34466C2 (uk) Засіб для несистемної боротьби з паразитуючими комахами
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
ATE255589T1 (de) Kristallin form i von clarithromycin
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
DK0973735T3 (da) Polyaromatiske antivirale præparater
DE69612003T2 (de) Substituierte benzolaktamverbindungen als substanz-p-antagonisten
NO965516D0 (no) Sterolderivater anvendt til regulering av meiose
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
ATE203519T1 (de) Chinolinderivate als antimalariamittel
DE69405919T2 (de) Zusammensetzungen zur Behandlung von Keratinfasern
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
NO980296L (no) Forbedrede terapeutiske midler
DE69613395D1 (de) Schwefelenthaltende di-ter-butylphenol-verbindungen brauchbar als entzündungshemmende mittel
ATE160573T1 (de) 1,3.5 (10) - estratriene derivate mit oraler wirkung
MD960168A (ro) Metodă şi compuşi pentru tratamentul infecţiilor virale
NO962221L (no) Anvendelse av dimeticon for behandling av konstipasjon
DE69917445D1 (de) Reinigung von carboxaldehyd
DK0720597T3 (da) Triarylethylenderivater til terapeutisk anvendelse
PT751775E (pt) Derivados de mercaptoacetilamida hipocolesterolemicos, antiateroscleroticos e hipotrigliceridemicos
ITRM920305A1 (it) Composizione farmaceutica per il trattamento dello shock, particolarmente dello shock cardiogeno e dello shock settico.
GR1001368B (el) Φαρμακευτικοί φορείς.
DE69428127D1 (de) Schädlingsbekämpfungsmittel